(IOSP) Innospec - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NASDAQ (USA) | Market Cap: 1.925m USD | Total Return: -5.4% in 12m
Avg Turnover: 15.3M
EPS Trend: -57.6%
Qual. Beats: -1
Rev. Trend: -96.1%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Innospec Inc. (IOSP) is a global specialty chemical company that develops and supplies additives and technology-based solutions across three primary segments: Performance Chemicals, Fuel Specialties, and Oilfield Services. Headquartered in Colorado, the firm supports diverse industries including personal care, aviation, maritime, and large-scale agriculture.
The specialty chemicals sector is characterized by high barriers to entry due to complex formulation requirements and proprietary technologies. Innospec utilizes a business model focused on chemical blending and customized engineering, which allows for higher margins compared to commodity chemical producers.
Investors can evaluate the company’s valuation metrics and historical performance trends by exploring the data available on ValueRay.
The company’s portfolio includes drag-reducing agents for oil pipelines and performance additives that improve fuel efficiency and reduce emissions in industrial engines. Its global distribution network serves multinational corporations, national oil companies, and independent exploration firms across four continents.
- Performance Chemicals margin expansion driven by personal care and sustainable surfactant demand
- Oilfield Services segment revenue tied to North American drilling and completion activity
- Fuel Specialties growth dependent on global aviation and marine transportation fuel additive volumes
- Raw material cost volatility impacts gross margins across the specialty chemical portfolio
- Strategic acquisitions and capital allocation efficiency influence long-term shareholder value creation
| Net Income: 114.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.54 > 1.0 |
| NWC/Revenue: 37.10% < 20% (prev 34.69%; Δ 2.42% < -1%) |
| CFO/TA 0.07 > 3% & CFO 127.6m > Net Income 114.2m |
| Net Debt (-238.5m) to EBITDA (167.7m): -1.42 < 3 |
| Current Ratio: 2.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.8m) vs 12m ago -1.03% < -2% |
| Gross Margin: 27.41% > 18% (prev 0.29%; Δ 2.71k% > 0.5%) |
| Asset Turnover: 99.62% > 50% (prev 100.6%; Δ -1.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.37 (Total Current Assets 999.1m - Total Current Liabilities 334.8m) / Total Assets 1.82b |
| B: 0.62 (Retained Earnings 1.13b / Total Assets 1.82b) |
| C: 0.07 (EBIT TTM 125.4m / Avg Total Assets 1.80b) |
| D: 2.33 (Book Value of Equity 1.09b / Total Liabilities 467.6m) |
| Altman-Z'' = 7.33 = AAA |
| DSRI: 1.03 (Receivables 354.2m/343.5m, Revenue 1.79b/1.79b) |
| GMI: 1.05 (GM 27.41% / 28.68%) |
| AQI: 0.99 (AQ_t 0.27 / AQ_t-1 0.27) |
| SGI: 1.00 (Revenue 1.79b / 1.79b) |
| TATA: -0.01 (NI 114.2m - CFO 127.6m) / TA 1.82b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 78.73 with a total of 183,296 shares traded.
Over the past week, the price has changed by +3.03%,
over one month by +7.40%,
over three months by +1.95% and
over the past year by -5.40%.
Innospec has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy IOSP.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 99.3 | 26.2% |
P/E Forward = 16.5289
P/S = 1.0751
P/B = 1.4901
P/EG = 0.6612
Revenue TTM = 1.79b USD
EBIT TTM = 125.4m USD
EBITDA TTM = 167.7m USD
Long Term Debt = 35.5m USD (estimated: total debt 50.6m - short term 15.1m)
Short Term Debt = 15.1m USD (from shortTermDebt, last quarter)
Debt = 50.6m USD (from shortLongTermDebtTotal, last quarter) (leases 52.7m already included)
Net Debt = -238.5m USD (calculated: Debt 50.6m - CCE 289.1m)
Enterprise Value = 1.69b USD (1.92b + Debt 50.6m - CCE 289.1m)
Interest Coverage Ratio = unknown (Ebit TTM 125.4m / Interest Expense TTM 0.0)
EV/FCF = 21.96x (Enterprise Value 1.69b / FCF TTM 76.8m)
FCF Yield = 4.55% (FCF TTM 76.8m / Enterprise Value 1.69b)
FCF Margin = 4.29% (FCF TTM 76.8m / Revenue TTM 1.79b)
Net Margin = 6.38% (Net Income TTM 114.2m / Revenue TTM 1.79b)
Gross Margin = 27.41% ((Revenue TTM 1.79b - Cost of Revenue TTM 1.30b) / Revenue TTM)
Gross Margin QoQ = 27.25% (prev 27.96%)
Tobins Q-Ratio = 0.93 (Enterprise Value 1.69b / Total Assets 1.82b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 50.6m)
Taxrate = 22.81% (9.10m / 39.9m)
NOPAT = 96.8m (EBIT 125.4m * (1 - 22.81%))
Current Ratio = 2.98 (Total Current Assets 999.1m / Total Current Liabilities 334.8m)
Debt / Equity = 0.04 (Debt 50.6m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = -1.42 (Net Debt -238.5m / EBITDA 167.7m)
Debt / FCF = -3.11 (Net Debt -238.5m / FCF TTM 76.8m)
Total Stockholder Equity = 1.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.35% (Net Income 114.2m / Total Assets 1.82b)
RoE = 8.68% (Net Income TTM 114.2m / Total Stockholder Equity 1.32b)
RoCE = 9.28% (EBIT 125.4m / Capital Employed (Equity 1.32b + L.T.Debt 35.5m))
RoIC = 6.73% (NOPAT 96.8m / Invested Capital 1.44b)
WACC = 8.97% (E(1.92b)/V(1.98b) * Re(9.21%) + D(50.6m)/V(1.98b) * Rd(0.0%) * (1-Tc(0.23)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -33.33 | Cagr: -0.36%
[DCF] Terminal Value 71.87% ; FCFF base≈79.8m ; Y1≈74.1m ; Y5≈67.1m
[DCF] Fair Price = 48.72 (EV 961.5m - Net Debt -238.5m = Equity 1.20b / Shares 24.6m; r=8.97% [WACC]; 5y FCF grow -9.00% → 2.50% )
EPS Correlation: -57.55 | EPS CAGR: -5.67% | SUE: -3.08 | # QB: -1
Revenue Correlation: -96.11 | Revenue CAGR: -4.62% | SUE: 1.03 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.04 | Chg30d=-10.73% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=1.21 | Chg30d=-10.37% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=4.82 | Chg30d=-4.74% | Revisions=-20% | GrowthEPS=-8.5% | GrowthRev=+4.7%
EPS next Year (2027-12-31): EPS=6.12 | Chg30d=-2.39% | Revisions=-20% | GrowthEPS=+27.1% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: -20%